GT Biopharma Inc (OTCQB: GTBP)(Euronext Paris GTBP.PA), a US headquartered immuno-oncology biotechnology company, announced yesterday that the company has promoted Dr Raymond W Urbanski MD, PhD to the position of president and chief medical officer, effective immediately.

Dr Urbanski will report to Shawn Cross, the company's chief executive officer.

Since joining the company in October 2017 Dr Urbanski has been instrumental in driving key milestones and initiatives including the transitioning the first TriKE IND from the University of Minnesota to GT Biopharma, while engaging the FDA in preparation for human clinical testing to begin in 2H 2018; implementing processes to expedite the identification and development of future tumour antigen targets; driving forward its Bi-specific Antibody Drug Conjugate platform, which included the formation of its Antibody-Drug Conjugate Clinical Advisory Board. GT also said that he has been a major factor in developing a strong working relationship with the University of Minnesota, Masonic Cancer Center, the epicentre of innovation for the TriKE and TetraKE platforms.